Mobile website
Archive > Volume 32 Issue 9 > 2025,32(9):899-905. DOI:10.3872/j.issn.1007-385X.2025.09.001 Prev Next
Expert Forum
Immune cell therapy for solid tumors: focus on bispecific antibody armed T/NK cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Adoptive cell therapy continues to drive innovation in cancer immunotherapy. Among the emerging approaches, bispecific antibody (BsAb)-armed T cell and NK cell (T/NK cell) technology leverages antibodies to specifically target tumor antigens and bridge immune effector cells, thereby endowing these cells with precise tumor-killing capabilities while overcoming the limitations of traditional therapeutic strategies. This technology is characterized by its high degree of standardization, controllable safety, and a short clinical translational cycle, demonstrating promising therapeutic potential in both solid tumors and hematologic malignancies. This article provides a comprehensive review of the advancements in chimeric antigen receptor-engineered T/NK cell (CAR-T/NK cell), tumor-infiltrating lymphocyte (TIL), and cytokine-induced memory-like NK cell (CIML NK) therapies. Particular emphasis is placed on the mechanisms of action, advantages, clinical progress, and emerging trends of BsAb-armed T/NK cell therapy.
Keywords:
Project Supported:
Clc Number:
